The IISPV’s Cancer Research Group aims to research the three main levels of oncological knowledge: population level, individual level, and molecular level.
Josep Gumà Padró
Joan Lluís Borràs Balada
At the population level, epidemiological data are studied from the Tarragona Cancer Registry and the results of population screening programs are reported.
From the individual point of view (patient-level), clinical trials are performed with new drugs or new combinations of the same in most tumor locations.
At the basic or molecular level, the Unit focuses on mutations in hereditary cancer, somatic tumor mutations, the relationship between lipids and cancer, and metabolomic studies in different tumors from both a diagnostic and prognostic point of view.
Clinical research
a. Clinical trials in phases II and III, and Real-World Studies of the main tumor locations.
b. Basket Trial-type clinical trials for tumors with certain genetic mutations.
c. Studies of prognostic and predictive response factors.
Epidemiological research
Responsible: Dr. Jaume Galceran
a. In the field of epidemiological research, it focuses on population-based studies related to the Tarragona Cancer Registry.
b. In the field of prevention research focuses on studies related to cancer screening.
Basic and translational research
a. Hereditary breast and ovarian cancer: a study of mutations of uncertain significance in BRCA genes, application of Next Generation Sequencing in the identification of new pathogenic mutations, and metabolomics of hereditary breast cancer cell lines.
Responsible: Dra. Marta Rodríguez
b. Precision oncology. Somatic study. Study of tumor mutations, including liquid biopsy, for clinical and research application, the basis of new therapeutic targets. Joint collaboration between the Pathological Anatomy Service, Medical Oncology and the Genetic Counseling Unit.
Responsible: Dr. Francesc Riu
c. Lipid metabolism and cancer: the role of fatty acid transporter proteins in tumor progression (Collaboration with the IISPV Lipid Unit).
Responsible: Dr. Josep Gumà / Dra. Sandra Guaita
d. Metabolomics: Metabolic profile in biological fluids for early diagnosis of colorectal cancer, as a predictor of response to immunotherapy in lung cancer, and as a prognostic factor in aggressive lymphomas.
Responsible: Dr. Josep Gumà
Research in psychooncology
Responsible: Dra. Agustina Sirgo
a. Study the impact of oncological disease. At the social level, the study of the benefits of the self-help group of women with breast cancer.
Maroto P, García Del Muro X, Valverde C, Pinto A, Sanchez A, Guma J, Alonso T, Martínez Del Prado P, Vazquez S, Mellado B, Aparicio J, Fernandez-Aramburo A, Girones R, Terrasa J; Spanish Germ Cell Cancer Group.Urol Oncol. 2020 Nov 11:S1078-1439(20)30573-1. doi: 10.1016/j.urolonc.2020.11.004. Epub ahead of print. PMID: 33189529.
Aparicio J, Terrasa J, Durán I, Germà-Lluch JR, Gironés R, González-Billalabeitia E, Gumà J, Maroto P, Pinto A, García-Del-Muro X. SEOM clinical guidelines for the management of germ cell testicular cancer (2016). Clin Transl Oncol. 2016 Dec;18(12):1187-1196. doi: 10.1007/s12094-016-1566-1. Epub 2016 Nov 4. PMID: 27815687; PMCID: PMC5138244.
Rueda Domínguez A, Alfaro Lizaso J, de la Cruz Merino L, Gumá i Padró J, Quero Blanco C, Gómez Codina J, Llanos Muñoz M, Martinez Banaclocha N, Rodriguez Abreu D, Provencio Pulla M. SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma. Clin Transl Oncol. 2015 Dec;17(12):1005-13. doi: 10.1007/s12094-015-1429-1. Epub 2015 Oct 26. PMID: 26497354; PMCID: PMC4689754.
Provencio Pulla M, Alfaro Lizaso J, de la Cruz Merino L, Gumá i Padró J, Quero Blanco C, Gómez Codina J, Llanos Muñoz M, Martinez Banaclocha N, Rodriguez Abreu D, Rueda Domínguez A. SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma. Clin Transl Oncol. 2015 Dec;17(12):1014-9. doi: 10.1007/s12094-015-1437-1. Epub 2015 Nov 19. PMID: 26586117; PMCID: PMC4689757.
Aldea A, Arriola E, Borràs JM, Bosch J, Carreras MJ, Conde D, Córdoba JF, Felip E, Fontanals S, Guarga L, Majem M, Mangues I, Martínez J, Moreno E, Nadal E, Peralta S, Rodríguez MC, Serrano G, Vilà L, Viñolas N. Programa d’harmonització farmacoterapèutica. Pautes per a l’harmonització del tractament farmacològic del càncer de pulmó no microcític metastàtic. Gasol M, Gay D, Guarga L, Martínez J, Puig G, Sancho A, Solós G coord. Pontes C, Ballano A Direcció. Barcelona: Servei Català de la Salut. Departament de Salut. Generalitat de Catalunya; 2021.
Responsible: Meritxell Arenas Prat
Responsible: Enric Figuerola Massana
Responsible: Antoni Castro Salomó
Responsible: Marylène Lejeune, Carlos López Pablo
